JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Simulations Plus Inc

Cerrado

SectorSanidad

15.13 -0.66

Resumen

Variación precio

24h

Actual

Mínimo

14.71

Máximo

15.63

Métricas clave

By Trading Economics

Ingresos

3.9M

4.5M

Ventas

5.9M

24M

BPA

0.35

Rentabilidad por dividendo

0.48

Margen de beneficios

18.669

Empleados

212

EBITDA

4.9M

7.2M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+4.51% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.24%

Próximas Ganancias

13 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

51M

302M

Apertura anterior

15.79

Cierre anterior

15.13

Noticias sobre sentimiento de mercado

By Acuity

6%

94%

7 / 348 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 abr 2026, 00:00 UTC

Noticias de Eventos Importantes

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 abr 2026, 23:33 UTC

Ganancias

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 abr 2026, 22:40 UTC

Ganancias

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 abr 2026, 22:10 UTC

Adquisiciones, fusiones, absorciones

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 abr 2026, 21:11 UTC

Ganancias

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 abr 2026, 21:01 UTC

Ganancias

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 abr 2026, 23:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

22 abr 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 abr 2026, 23:34 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 abr 2026, 23:16 UTC

Ganancias

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 abr 2026, 23:15 UTC

Ganancias

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 abr 2026, 22:54 UTC

Ganancias

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 abr 2026, 22:54 UTC

Ganancias

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 abr 2026, 22:52 UTC

Ganancias

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 abr 2026, 22:51 UTC

Ganancias

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 abr 2026, 22:31 UTC

Ganancias

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 abr 2026, 22:31 UTC

Ganancias

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 abr 2026, 22:30 UTC

Ganancias

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 abr 2026, 22:30 UTC

Ganancias

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 abr 2026, 22:29 UTC

Ganancias

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 abr 2026, 22:28 UTC

Ganancias

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 abr 2026, 22:28 UTC

Ganancias

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 abr 2026, 22:27 UTC

Ganancias

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 abr 2026, 22:06 UTC

Charlas de Mercado
Ganancias

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 abr 2026, 21:55 UTC

Adquisiciones, fusiones, absorciones

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 abr 2026, 21:47 UTC

Ganancias

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 abr 2026, 21:37 UTC

Ganancias

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 abr 2026, 21:34 UTC

Ganancias

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 abr 2026, 21:29 UTC

Ganancias

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 abr 2026, 21:20 UTC

Charlas de Mercado
Ganancias

Tesla Expands Manufacturing to Chips -- Market Talk

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

4.51% repunte

Estimación a 12 Meses

Media 16 USD  4.51%

Máximo 16 USD

Mínimo 16 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

7 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat